AlloVir, Inc. (NASDAQ:ALVR) Sees Large Increase in Short Interest

AlloVir, Inc. (NASDAQ:ALVR) was the recipient of a significant growth in short interest in November. As of November 30th, there was short interest totalling 1,920,000 shares, a growth of 57.4% from the November 15th total of 1,220,000 shares. Based on an average daily trading volume, of 321,500 shares, the days-to-cover ratio is presently 6.0 days.

Institutional Trading of AlloVir

A number of institutional investors and hedge funds have recently made changes to their positions in ALVR. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of AlloVir during the 2nd quarter worth approximately $55,000. Price T Rowe Associates Inc. MD grew its holdings in AlloVir by 127.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 97,986 shares of the company’s stock worth $74,000 after buying an additional 54,900 shares in the last quarter. Finally, Cubist Systematic Strategies LLC grew its holdings in AlloVir by 152.3% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 49,816 shares of the company’s stock worth $36,000 after buying an additional 30,072 shares in the last quarter. 66.05% of the stock is currently owned by institutional investors and hedge funds.

AlloVir Stock Down 2.2 %

Shares of AlloVir stock traded down $0.01 on Friday, reaching $0.45. 464,442 shares of the company were exchanged, compared to its average volume of 599,591. The company’s 50-day moving average is $0.70 and its two-hundred day moving average is $0.74. AlloVir has a 1-year low of $0.44 and a 1-year high of $2.49.

AlloVir (NASDAQ:ALVR) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10.

About AlloVir

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.